Has Maureen Mayes, MD received payments from drug or device companies?

Yes. Drug and device makers reported $83,756 in general payments to Maureen Mayes, MD across 153 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Maureen Mayes, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Maureen Mayes, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Maureen Mayes, MD

Rheumatology · Houston, TXNPI 1255364238

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 33.0% of the total. Among rheumatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$83,756in general payments, 2019–2025

Across 153 payments — averaging $547.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim International GmbH$28K
Merck$17K
Astrazeneca UK Limited$15K
GSK$8K
Argenx US, Inc.$5K
Novartis$3K
plus $9K from 10 others

$1,491,633in research payments, 2019–2025

Across 182 payments — averaging $8195.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$674K
Boehringer Ingelheim$329K
Seagen Inc.$137K
AstraZeneca$131K
Bristol Myers Squibb$58K
Tanabe Pharma America, Inc.$46K
plus $117K from 8 others

What the payments were for

Consulting fees$49,43459%
Speaking & faculty fees$23,02927%
Travel & lodging$7,7139%
Food & beverage$3,5804%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim International GmbH	59	$27,679
Merck	26	$16,843
Astrazeneca UK Limited	11	$14,622
GSK	4	$8,156
Argenx US, Inc.	2	$5,400
Novartis	14	$2,524
Boehringer Ingelheim	10	$1,965
E.r. Squibb & Sons, L.L.C.	2	$1,622
CSL Behring	9	$1,611
Actelion Pharmaceuticals US, Inc.	1	$1,550
Boehringer Ingelheim Pharma GmbH & Co.kg	1	$1,065
AbbVie	4	$351
UCB, Inc.	2	$188
AstraZeneca	4	$90
Tanabe Pharma America, Inc.	1	$52
Johnson & Johnson	3	$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OFEV$29,042
SAPHNELO$14,260
BENLYSTA$7,661
VYVGART HYTRULO$5,000
OPSUMIT$1,550
Privigen$1,278
Rinvoq$221
Humira$108

How this compares

$83,756 in reported general payments places this provider in the 90th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas →

Medicare billing

Part B allowed, 2024

$17,193

Medicare patients

Services billed

160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XeljanzTofacitinib Citrate	12	$68,905
Mycophenolate Mofetil	57	$18,506
Sildenafil Citrate	22	$8,367
Hydroxychloroquine Sulfate	29	$793
Omeprazole	28	$612
Prednisone	73	$523
Gabapentin	11	$261
Amlodipine Besylate	41	$195
MethotrexateMethotrexate Sodium	15	$146
Pantoprazole Sodium	15	$141
Zolpidem Tartrate	18	$77
Cilostazol	12	$46

Paid to pharmacies, not to this prescriber.

Other rheumatology in Houston

Naureen AlimHouston$397K
Shervin AssassiHouston$329K
Tareq Abou-KhamisHouston$116K
Maria Suarez AlmazorHouston$72K
John ReveilleHouston$61K
Michelle EisenbergHouston$53K
Alfredo SardinasHouston$52K
Adnan PeerHouston$49K
Mujahed AlikhanHouston$41K
Dianne WollastonHouston$39K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →